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ABSTRACT
Introduction Metabolic syndrome (MetS) is an important 
predictor of cardiovascular mortality. Identification of 
occurrence and regression trends of MetS could permit 
elaboration of preventive strategies with new targets. The 
objective of this study was to analyze the occurrence and 
regression rates of MetS and its associated factors in the 
representative cohort of Spain of the  di@ bet. es study.
Research design and methods The  di@ bet. es study is 
a prospective cohort where 5072 people representative of 
the Spanish population over 18 years of age were randomly 
selected between 2009 and 2010. Follow- up was a median 
of 7.5 (IQR 7.2–7.9) years, with 2408 (47%) participating 
subjects. A total of 1881 (78%) subjects had all the pertinent 
data available and were included in this study.
Results Of the 1146 subjects without baseline criteria for 
MetS, 294 (25.7%) developed MetS during follow- up, while 
of the 735 patients with prior MetS, 148 (20.1%) presented 
regression. Adjusted MetS incidence per 1000 person- years 
was 38 (95% CI 32 to 44), while regression incidence was 36 
(95% CI 31 to 41). Regression rate was independently higher 
than incidence rate in the following: women, subjects aged 
18–45, university- degree holders, patients without central 
obesity, without hypertension, as well as those with body 
mass index of <25 kg/m2. Lower progression and higher 
regression rates were observed with an adapted 14- point 
Mediterranean Diet adherence screener questionnaire score 
of >11 in both groups and with >500 and>2000 MET- min/
week of physical activity, respectively.
Conclusions This study provides MetS incidence and 
regression rates, and identifies the target population for 
intervention strategies in Spain and possibly in other 
countries.
INTRODUCTION
Metabolic syndrome (MetS) is the combina-
tion of a range of metabolic disorders that 
include central obesity, abnormal glucose 
Significance of this study
What is already known about this subject?
 ► Metabolic syndrome (MetS) is one of the main pre-
dictors of cardiovascular mortality.
 ► Knowing the trends of occurrence and regression 
of the MetS and its associated factors can allow 
defining preventive strategies and new targets to 
intervene.
What are the new findings?
 ► Adjusted MetS incidence per 1000 person- years 
was 38 (95% CI 32 to 44), while regression inci-
dence was 36 (95% CI 31 to 41).
 ► Regression rate was independently higher than 
incidence rate in the following: women, subjects 
aged 18–45, university- degree holders, patients 
without central obesity, without hypertension, 
as well as those with a body mass index of 
<25 kg/m2.
 ► To reduce the occurrence of MetS it is neces-
sary to achieve a higher degree of adherence to a 
Mediterranean diet.
How might these results change the focus of 
research or clinical practice?
 ► This study provides MetS incidence and regression 
rates and identifies the target population for inter-
vention strategies in Spain and possibly in other 
countries. Lower progression and higher regres-
sion rates were observed with an adapted 14- point 
Mediterranean Diet adherence screener question-
naire score of >11 in both groups and with >500 
and >2000 MET- min/week of physical activity, 
respectively.
 ► Researchers should further investigate how lifestyle 
can be optimized for health promotion and preven-
tion of MetS.
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regulation, atherogenic dyslipidemia and arterial hyper-
tension coexisting in the same individual, predisposing 
to cardiovascular disease (CVD) and type 2 diabetes 
mellitus (T2DM). The definition of MetS was agreed 
by different scientific societies during the last decade,1 
recommending the use of specific waist circumference 
measurements adapted to each population. Its funda-
mental component is represented by visceral obesity. 
The relevance of the MetS lies on doubling the risk of 
CVD between 5 and 10 years following the diagnosis, 
and the occurrence of T2DM by 5 years. The preva-
lence in Spain reached just over 42% of men and 32% 
of women in 2010.2 Since then, national strategies for 
the prevention of T2DM and obesity have been rein-
forced.3 4
The Diabetes Prevention Program (DPP) study demon-
strated the regression from pre- diabetes to normal 
glucose regulation achieved by the reduction of body 
weight5 6 and was also associated with a reduction in a 
wide range of microvascular complications.7 These find-
ings explain why so much emphasis has been placed on 
obesity programs/interventions. Regression from pre- 
diabetes and T2DM has been consistently found after 
surgical treatment of obesity in several series8–11 Consid-
ering that the clinical presentation of the MetS can 
evolve in two directions, occurrence and regression, both 
reducing its occurrence and facilitating its regression are 
equally important. In order to assess the efficacy of any 
intervention, the same population should be assessed 
simultaneously during the same period of time. So far, 
only the DPP has simultaneously analyzed the reduc-
tion in the risk for progression to type 2 diabetes (8%) 
and the regression to normal glucose regulation (35%) 
through an intensive lifestyle intervention or metformin 
treatment in overweight or obese subjects with impaired 
glucose regulation at low risk of developing T2DM.6 
Other components of the MetS have not been evaluated 
prospectively, and to our knowledge, the determinants 
associated with the regression or progression of the MetS 
are unknown.
The  di@ bet. es cohort was selected between 2009 and 
2010 from the five basic healthcare units and was built 
from a representative sample of subjects of the non- 
institutionalized Spanish population. Its main objective 
was to evaluate the prevalence of T2DM based on the 
oral glucose tolerance test (OGTT), in order to define 
preventive strategies developed at the population level 
and plan improvements.3 4 Our group has published 
previously the prevalence of T2DM12 and MetS2 from the 
data collected during the  di@ bet. es study. The cohort of 
subjects was followed up prospectively until 2016–2017, 
when a cross- sectional study was undertaken. The main 
aim of this study was to address the rate of progression of 
the subjects who were not diagnosed with MetS at base-
line and the rate of regression of the subjects who did, 
and to analyze the determinants associated with both 
situations.
RESEARCH DESIGN AND METHODS
Population
A total of 5072 subjects over 18 years of age were randomly 
selected from the National Health System registry of 
users (covering over 99% of the Spanish population). 
This sample is representative of the non- institutionalized 
Spanish population. A broader description of the study 
design was previously published.12 The cohort was 
re- evaluated during 2016–2017. A total of 2408 subjects 
participated in the follow- up analysis. The characteristics 
of non- responders and responders have been recently 
reported.13
A total of 1881 (78%) subjects had all the necessary 
information available for each of the MetS components at 
baseline and at follow- up. The subjects were divided into 
two groups: group A, without MetS at baseline (n=1146), 
and group B, with MetS at baseline (n=735). The charac-
teristics of the patients are shown in table 1.
MetS definition
MetS was defined according to the Harmonized defi-
nition1 using the specific waist circumference (WC) 
measurement of the Spanish population (94.5 cm in men 
and 89.5 cm for women) based on a Spanish population 
study14 and confirmed in the baseline study2 as the cut- off 
points with the highest sensitivity and specificity. The cut- 
off points for the rest of the components were −blood pres-
sure (BP)>130/85 mm Hg, −triglyceride (TG)>150 mg/
dL (1.7 mmol/L), −glucose>100 mg/dL (5.6 mmol/L) 
and −HDL- chol less than 40 mg/dL (1 mmol /L) for 
men and 50 mg/dL (1.3 mmol/L) for women. Subjects 
who received appropriate pharmacological treatment for 
hypertension, dyslipidemia or impaired glucose toler-
ance/diabetes were considered as having the respective 
risk factors. In order to establish the diagnosis of the 
MetS at least three abnormal components were required. 
Subjects who withdraw pharmacological treatment and 
were under the cut- off points were considered as having 
a regression for the respective component of the MetS.
Outcomes
In group A, the rate of the MetS occurrence was evalu-
ated, in the subjects who fulfilled <3 criteria at baseline 
and who fulfilled ≥3 criteria during follow- up, and in 
group B, the regression rate of the MetS was evaluated in 
the subjects fulfilling ≥3 criteria at baseline and <3 at the 
follow- up visit, respectively.
Variables and procedures
The subjects were received in the laboratory of their 
healthcare unit between 08:00 and 09:00, after at least 
10 hours of fasting. After signing the informed consent, 
a blood sample was obtained to analyze the levels of 
glucose (hexokinase enzymatic method), total choles-
terol (cholesterol enzymatic method), HDL- chol (direct 
method), low- density lipoprotein cholesterol (Friede-
wald formula) and TGs (glycerol phosphate oxidase 
enzymatic method). Capillary blood glucose (One Touch 
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System, LifeScan, Johnson & Johnson, S.A., Madrid) was 
determined. If the capillary glucose was less than 126 mg/
dL (7.8 mmol/L), a sample was obtained 2 hours after 
75 g OGTT. A face- to- face interview was then conducted 
with a trained nurse, structured questionnaires on health 
status and lifestyle were applied, and a physical examina-
tion was performed.
Physical exam: weight without heavy clothing and 
height, in order to calculate the body mass index [BMI=-
weight (kg)/height2 (m)], waist circumference (cm), BP 
with an appropriately sized cuff in a sitting position after 
5 min of rest, taking three measurements 2 min apart with 
the last one being considered.
Sociodemographic variables: the following variables 
obtained in both phases were considered: age, educa-
tional level (categorized as no studies, elementary, 
secondary education and university degree), socioeco-
nomic status (salaried worker, retired, unemployed, 
student, domestic work and others), family status 
(married or cohabiting, single, widowed or separated). 
Family history for first- degree relatives with T2DM was 
also collected.
Questionnaires: The questionnaires were applied in 
a face- to- face interview conducted by a trained nurse. 
The health questionnaire included the assessment of 
previous diseases, the family medical history and the 
pharmacological treatments that subjects were taking 
in order to determine the presence of clinical diabetes, 
hypertension or dyslipidemia. The level of physical 
activity was evaluated by applying the International 
Physical Activity Questionnaire (IPAQ)15 16 to transform 
into metabolic equivalent of task (MET) the duration 
Table 1 Characteristics of the study population stratified by absence (group A) or presence (group B) of metabolic syndrome 
at baseline
All sample Group A Group B P value
Number 1881 1146 735
Men 802 (42.6) 419 (36.6) 383 (52.1) <0.001
Women 1079 (57.4) 727 (63.4) 352 (47.9)
Age (years) 50.22±14.47 46.06±13.90 56.69±12.89 <0.001
Body weight (kg) 75.02±14.91 70.03±12.75 82.83±14.71 <0.001
BMI (kg/m2) 28.18±4.97 26.23±3.98 31.23±4.84 <0.001
WC (cm)
  Men 98.93±11.07 93.41±9.83 104.96±9.02 <0.001
  Women 90.82±14.27 85.32±11.69 102.18±12.28 <0.001
SBP (mm Hg) 130.89±18.98 123.93±16.73 141.76±17.08 <0.001
DBP (mm Hg) 77.00±10.29 73.95±9.57 81.77±9.53 <0.001
FG (mmol/L) 5.52±1.52 5.05±0.81 6.26±2.01 <0.001
Total- chol (mmol/L) 5.12±1.01 5.06±0.97 5.22±1.07 0.005
TG (mmol/l) 1.37±1.05 1.06±0.47 1.87±1.44 <0.001
HDL- chol (mmol/L) 1.35±0.33 1.45±0.32 1.21±0.29 <0.001
LDL- chol (mmol/L) 2.75±0.76 2.69±0.73 2.85±0.79 <0.001
Obesity (≥30 kg/m2) 571 (30.4) 182 (15.9) 389 (52.9) <0.001
Uric acid (μmol/L) 307.09±88.66 283.52±80.60 343.82±88.21 <0.001
Educational level <0.001
  No studies 197 (10.5) 63 (5.5) 134 (18.3)
  Elementary 702 (37.3) 393 (34.3) 309 (42.0)
  Secondary education 671 (35.7) 450 (39.3) 221 (31.1)
  University degree 148 (7.9) 240 (20.9) 71 (9.6)
Socioeconomic status <0.001
  Salaried worker 937 (49.8) 640 (55.8) 297 (40.4)
  Retired 333 (17.7) 141 (12.3) 192 (26.1)
  Unemployed 154 (8.2) 110 (9.6) 44 (6.0)
  Student 46 (2.4) 43 (3.8) 3 (0.4)
  Domestic work 366 (19.5) 190 (16.6) 176 (23.9)
  Others 45 22 23
Data are mean±SD or n (%).
BMI, body mass index; DBP, diastolic blood pressure; FG, fasting serum glucose; HDL- chol, high- density lipoprotein cholesterol; LDL- chol, low- 
density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride; Total- chol, total cholesterol; WC, waist circumference.
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and frequency of low, moderate and vigorous activities 
and all walking to the activities declared during the 
previous week. They were classified into one of these 
three categories: low, moderate or high expenditure, 
according to a previous study,17 and the total energy 
expenditure of all physical activities was also calculated 
as MET- min/week of physical activity. The adapted 
14- point MedDiet adherence screener (MEDAS) ques-
tionnaire18 was applied to estimate adherence to the 
Mediterranean diet, after applying a qualitative food 
frequency questionnaire of 50 foods items. The cut- off 
point of 9 was considered to reflect high or low adher-
ence to the Mediterranean diet.
Statistical study
Qualitative variables were summarized by their 
frequency distribution as well as quantitative variables 
by their mean±SD). The continuous non- normally 
distributed variables were summarized by the median 
and IQR: (P25–P75). Differences in variables according 
to the presence or absence of MetS were determined 
by the t- test for independent samples or the Mann- 
Whitney test when appropriate for quantitative vari-
ables and χ2 test for qualitative variables. The sample 
incidence rates (IRs) for MetS or regression were 
calculated as number of events/person- time at risk, 
assuming a constant incidence over time. The IR was 
calculated adjusted for sex and age by direct method 
using as reference the Spanish population (https://
www. ine. es/, accessed June 2009).
Univariate analysis for the incidence or regression of 
MetS was performed using logistical regression. For IRs 
and ORs obtained in logistic regression, 95% CIs were 
computed. A multivariate logistic regression model was 
fitted to identify the factors that were independently 
related to the incidence or regression of MetS. The vari-
ables for the adjustment were those which, in the univar-
iate analyses, showed a level of statistical significance of 
p<0.05 and/or were considered clinically relevant. A 
first model (model 1) was adjusted by introducing the 
following variables: age (categorized as 18–45, 46–60, 
61–75 and ≥76), gender, educational level (categorized 
as university degree or no university degree), marital 
status (categorized as married/cohabiting or others) 
and number of components of MetS. A second model 
was adjusted by adding the basic healthcare units to the 
variables of the first model (model 2). All analyses were 
performed using SPSS V.21.0 and STATA V.15.0 soft-
ware. Statistical significance was assumed p<0.05.
RESULTS
Over a median follow- up of 7.5 (IQR 7.2–7.9) years, 
MetS developed in 294 (25.7%) subjects in group A. 
With 8646 person- years, the adjusted incidence (95% CI) 
per 1000 person- years was 38 (32-44), affecting more in 
men, increasing with age, in those with the lowest educa-
tional level and with the presence of 1 or 2 components 
of the MetS at baseline. The OR increases in overweight 
people 4.48 (95% CI 3.12 to 6.43), obesity 9.53 (95% CI 
6.25 to 14.55) and with central fat distribution 4.16 
(95% CI 3.12 to 5.44). The mean differences between 
the non- progressors compared with the progressors in 
the adapted MEDAS (9.2±1.4 vs 9.2±1.4, –0.0 (–0.2 to 
0.2, p=0.519) and the median (IQR) MET- min/week of 
physical activity (1074 (396–3021) vs 1048 (394–3360), 
p=0.875) were not statistically significantly different. The 
probability of progression per 1000 person- years was 
observed by an adapted MEDAS score of >11 (31 (16–55) 
vs 34 (30–38)) in those with ≤11, but not by 9. Similarly, 
the probability decreases slightly as physical activity 
increases, and this trend is particularly observed in those 
who spent more than 500 MET- min/week (31 (25–39) vs 
36 (29–43)) in those with ≤500 MET- min/week, respec-
tively. These results are presented in table 2.
Regression occurred in 148 (20.1%) patients in group 
B, who fulfilled the criteria for MetS at baseline. With a 
follow- up of 5556 person- years, the adjusted regression 
rate per 1000 person- years was 36 (95% CI 31 to 41). 
The regression was more frequently observed in women, 
and especially in subjects fulfilling only three criteria of 
the MetS at baseline with an OR of 5.98 (2.36–15.15) 
compared with those with five criteria at baseline (refer-
ence group). The ORs in subjects without hypertension 
for MetS regression was 2.84 (1.75–4.61) and 1.77 (1.22–
2.57) for those without hypertriglyceridemia, respec-
tively. The likelihood of MetS regression decreases as 
body weight increases, with an ORs of 0.23 (0.11–0.49) 
in overweight subjects at baseline and 0.12 (0.06–0.26) 
in obese.
There were no differences in the adapted MEDAS score 
and in the physical activity obtained by the MET- min/
week in the group of regressors compared with the non- 
repressors of MetS. The comparison of the mean score 
in the adapted MEDAS questionnaire in the regressors 
compared with the non- regressors was 8.9±1.3 vs 9.2±1.4, 
−0.3 (−0.6 to 0.1), p=0.543. Similarly, the comparison 
of the median between regressors and non- regressors 
in MET- min/week expenditure of physical activity was 
876 (IQR 231–2772) vs 693 (IQR 231–2544), p=0.387. 
The regression rate per 1000 person- years of the MetS 
was greater in people who achieved an adapted MEDAS 
score of >11 (34 (11–78) vs (26 (22–31)) in those with 
≤11 but not with 9. Similarly, a greater probability of MetS 
regression was observed when the subjects reached a 
MET- min/week expenditure of physical activity of >2000 
MET- min/week (30 (23–40) vs 23 (17–33)) in those with 
<2000 MET- min/week, respectively. The data on the 
MetS regression (group B) are displayed in table 3.
Multivariate analysis adjusted by significant variables 
in univariate analysis (model 1) and adding basic health-
care units (model 2) showed no effect in the association 
factors with the progression/regression of MetS (online 
supplemental table 1).
The MetS regression rate was significantly higher than 
the MetS incidence in women, university- level subjects, 
5BMJ Open Diab Res Care 2020;8:e001715. doi:10.1136/bmjdrc-2020-001715
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Table 2 Incidence of MetS in group A according to characteristics at baseline
At risk (n) Developing MetS (n) P value OR (95% CI) Person- year
Incidence per 1000 
person- years (95% CI)
All samples 1146 294 (25.7) 8646 38 (32 to 44)
Gender
  Men 419 153 (36.5) 2.39 (1.82 to 3.13) 3166 48 (41 to 57)
  Women 727 141 (19.4) 0.000 1 5480 26 (22 to 30)
Age (years)
  18–45 592 85 (14.4) 1 4452 19 (15 to 24)
  46–60 361 114 (31.6) 2.75 (2.00 to 3.79) 2730 42 (35 to 50)
  61–75 172 83 (48.3) 5.56 (3.82 to 8.11) 1305 64 (51 to 79)
  ≥76 21 12 (57.1) 0.000 7.95 (3.25 to 19.45) 160 75 (39 to 131)
Marital status
  Single 218 39 (17.9) 1 1650 24 (17 to 32)
  Married/cohabiting 836 235 (28.1) 1.80 (1.23 to 2.62) 6292 37 (33 to 42)
  Widower 43 10 (23.3) 1.39 (0.63 to 3.06) 327 31 (15 to 56)
  Divorced 49 10 (20.4) 0.016 1.18 (0.54 to 2.56) 378 27 (13 to 49)
Educational level
  No studies 62 34 (38.7) 3.70 (1.98 to 6.91) 471 51 (33 to 76)
  Elementary 527 160 (30.4) 2.55 (1.71 to 3.82) 3973 40 (34 to 47)
  Secondary education 316 75 (23.7) 1.82 (1.17 to 2.84) 2380 32 (25 to 40)
  University degree 240 35 (14.8) 0.000 1 1814 19 (13 to 27)
Region of the country
  North 135 26 (19.3) 1 1040 25 (16 to 37)
  South 447 122 (27.3) 1.57 (0.98 to 2.53) 3341 37 (30 to 44)
  Centre 291 85 (29.2) 1.73 (1.05 to 2.84) 2221 38 (31 to 47)
  Northeast 117 26 (22.2) 1.20 (0.65 to 2.21) 916 28 (19 to 42)
  East coast 156 35 (22.4) 0.135 1.21 (0.69 to 2.14) 1127 31 (22 to 43)
Number of components of MetS
  0 294 16 (5.4) 1 2219 7 (4 to 11)
  1 401 72 (18.0) 3.80 (2.16 to 6.69) 3023 24 (19 to 30)
  2 451 206 (45.7) 0.000 14.61 (8.54 to 24.99) 3404 61 (53 to 69)
Glucose regulation
  Normal 885 214 (24.2) 1 6675 32 (28 to 37)
  >99 261 80 (30.7) 0.023 1.39 (1.02 to 1.88) 1971 41 (32 to 51)
HDL- chol low
  No 968 245 (25.3) 1 7303 34 (30 to 38)
  Yes 178 49 (27.5) 0.296 1.21 (0.78 to 1.61) 1343 37 (27 to 48)
Central obesity
  No 750 120 (16.0) 1 5684 21 (18 to 25)
  Yes 396 174 (43.9) 0.000 4.16 (3.12 to 5.44) 2962 59 (50 to 68)
Hypertension
  No 736 141 (19.2) 1 5531 26 (22 to 30)
  Yes 410 153 (37.3) 0.000 2.51 (1.92 to 3.30) 3115 49 (42 to 58)
Hyper- TG
  No 1088 266 (24.4) 1 8206 32 (29 to 37)
  Yes 58 28 (48.3) 0.000 2.89 (1.69 to 4.92) 440 64 (42 to 92)
BMI (kg/m2)
  18–<25 474 45 (9.5) 0.000 1 3582 13 (9 to 17)
  25–<30 488 156 (32.0) 4.48 (3.12 to 6.43) 3683 42 (36 to 50)
  >30 182 91 (50.0) 9.53 (6.25 to 14.55) 1366 67 (54 to 82)
Continued
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subjects with no central fat distribution, overweight or 
obesity, and without hypertension (all p<0.05).
DISCUSSION
According to the data obtained in our study, the inci-
dence of MetS in a representative sample of the Spanish 
population is 38 cases per 1000 person- years but, on the 
contrary, regresses in 36 cases per 1000 person- years. 
This means that the MetS rate increases 2 cases per 1000 
person- years in excess in relation to the regression rate, 
which for a population of 47 million people represents an 
increase in approximately of 94 000 cases per year, with 
about 257 more patients diagnosed with MetS daily.
This study has provided important information to 
identify the characteristics of progressors to MetS. The 
appearance of the MetS is significantly higher in men, 
in the age group over 45 years and in those who do not 
reach a university level, as reported in the baseline study. 
Those with at least one component of the MetS are 
four times more likely to develop it and if they have two 
components/criteria at baseline, about 15 times higher 
compared with those fulfilling no criteria at baseline. 
These results are in agreement to those reported in other 
populations,19–22 probably indicating a slow progression 
in the occurrence of MetS. Although the presence of any 
component increases the probability of presenting MetS, 
the most determining factors are waist circumference, 
which multiplies the risk by 4, while being overweight or 
obese multiplies by more than nine times the probability 
of developing the MetS. The implications of these find-
ings are that programs aimed to reduce body weight are 
essential to reduce the incidence of the MetS in Spain. 
Unexpectedly, a correct adherence to the Mediterranean 
diet evaluated by MEDAS is not associated with a reduc-
tion in the occurrence of MetS, if we define 9 as the cut- 
off point referred to identify adherents to Mediterranean 
diet (Med Diet), as identified in the PREDIMED study in 
the prevention of T2DM.18 23 However, PREDIMED study 
also found no association with the occurrence or regres-
sion of the MetS.24
Using other questionnaires as tools to assess the adher-
ence to the Med Diet and in a Spanish population with a 
high educational level, such as alumni from the Univer-
sity of Navarra in the SUN (Seguimiento Universidad de 
Navarra) study, a significant reduction in MetS occur-
rence was found associated with a higher level of adher-
ence to Med Diet.21 In our study, using other cut points, 
such as 11, we found that there is a trend to a decreased 
rate of occurrence, indicating that to reduce the occur-
rence of MetS, it is likely to be necessary to achieve a 
higher degree of adherence to Med Diet. On the other 
hand, we must consider that the MEDAS median in 
our cohort is nine and that the score greater than 7 is 
exceeded by 98% of the cohort included in the study. 
Thus, we can consider that in a population with a high 
degree of adherence to Med Diet, it may be necessary 
to achieve a higher adherence to Med Diet to observe 
benefits.25 26 A larger sample size may also be necessary to 
observe a more favorable effect.
Regarding physical activity, there is a slight linear 
reduction in the appearance of MetS with moderate 
and high intensity; it begins to be favorable from being 
moderately active, that is, from 500 MET- min/week of 
physical activity. Physical activity has substantial beneficial 
effects on MetS.27 There is agreement that being active, 
even at a low level, can be sufficient for the prevention 
At risk (n) Developing MetS (n) P value OR (95% CI) Person- year
Incidence per 1000 
person- years (95% CI)
IPAQ
  High 278 69 (24.8) 0.933 1 2103 33 (26 to 42)
  Moderate 387 99 (25.6) 1.04 (0.73 to 1.49) 2921 34 (28 to 41)
  Low 480 125 (26.0) 1.07 (0.76 to 1.50) 3614 35 (29 to 41)
MET- min/week
  >500 777 194 (25.0) 0.241 1 3320 31 (25 to 39)
  ≤500 369 100 (27.1) 1.12 (0.84 to 1.48) 2773 36 (29 to 43)
MEDAS
  <9 345 85 (24.6) 0.330 1 2587 33 (26 to 41)
  >9 801 209 (26.1) 1.08 (0.81 to 1.45) 6059 35 (30 to 40)
  ≤11 1095 282 (25.8) 0.434 1.28 (0.58 to 2.18) 8266 34 (30 to 38)
  >11 51 12 (23.5) 1 379 31 (16 to 55)
Family history of T2DM
  No 528 134 (25.4) 0.425 1 3944 34 (28 to 40)
  Yes 595 155 (26.1) 1.04 (0.79 to 1.35) 4476 35 (29 to 41)
Data are n (%).
BMI, body mass index; HDL- chol, high- density lipoprotein cholesterol; IPAQ, International Physical Activity Questionnaire; MEDAS, Mediterranean Diet adherence 
screener; MET, metabolic equivalent of task; MetS, metabolic syndrome; T2DM, type 2 diabetes mellitus; TG, triglyceride.
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Table 3 Regression of MetS in group B according to characteristics at baseline
At risk (n)
Regression to no 
MetS (n) P value OR (95% CI) Person- year
Incidence per 1000 
person- years (95% CI)
All samples 735 148 (20.1) 5556 36 (31 to 41)
Gender
  Men 383 59 (15.4) 1 2911 20 (15 to 26)
  Women 352 89 (25.3) 0.001 1.86 (1.29 to 2.68) 2645 34 (27 to 41)
Age (years)
  18–45 146 42 (28.8) 1.77 (0.76 to 4.12) 1092 39 (28 to 52)
  46–60 265 51 (19.2) 1.04 (0.46 to 2.38) 1998 26 (19 to 34)
  61–75 281 47 (16.7) 0.88 (0.38 to 2.01) 2135 22 (16 to 29)
  >76 43 8 (18.6) 0.029 1 330 24 (11 to 48)
Marital status
  Single 61 17 (27.9) 1 465 37 (21 to 59)
  Married/cohabiting 605 119 (19.7) 0.63 (0.35 to 1.15) 4579 26 (22 to 31)
  Widower 46 7 (15.2) 0.47 (0.17 to 1.24) 342 21 (8 to 42)
  Divorced 23 5 (21.7) 0.380 0.72 (0.23 to 2.24) 169 30 (10 to 69)
Educational level
  No studies 134 23 (17.2) 1 1013 23 (14 to 34)
  Elementary 387 76 (19.6) 1.18 (0.71 to 1.97) 2931 26 (20 to 32)
  Secondary education 143 33 (23.1) 1.45 (0.80 to 2.62) 1072 31 (21 to 43)
  University degree 71 16 (22.5) 0.611 1.40 (0.69 to 2.87) 540 30 (17 to 48)
Region of the country
  North 68 19 (27.9) 1 531 36 (22 to 56)
  South 285 57 (20.0) 0.65 (0.35 to 1.18) 2100 27 (21 to 35)
  Center 205 32 (15.6) 0.48 (0.25 to 0.91) 1589 20 (14 to 28)
  Northeast 83 19 (22.9) 0.77 (0.37 to 1.60) 653 29 (18 to 45)
  East coast 94 21 (22.3) 0.209 0.74 (0.36 to 1.52) 684 31 (19 to 47)
Number of components of MetS
  3 408 111 (27.2) 5.98 (2.36 to 15.15) 3086 36 (30 to 43)
  4 242 32 (13.2) 2.44 (0.92 to 6.48) 1835 17 (12 to 25)
  5 85 5 (5.9) 0.000 1 635 8 (3 to 18)
Glucose regulation
  Normal 145 37 (25.5) 1.48 (0.97 to 2.27) 1095 34 (24 to 47)
  >99 580 111 (18.8) 0.048 1 4461 25 (21 to 30)
HDL- chol, low
  No 386 74 (19.2) 0.88 (0.62 to 1.26) 2924 25 (20 to 32)
  Yes 349 74 (21.2) 0.276 1 2632 28 (22 to 35)
Central obesity
  No 58 17 (29.3) 1.73 (0.95 to 3.14) 436 39 (23 to 62)
  Yes 677 131 (19.4) 0.054 1 5120 26 (21 to 30)
Hypertension
  No 84 32 (38.1) 2.84 (1.75 to 4.61) 627 51 (35 to 72)
  Yes 651 116 (17.8) 0.000 1 4929 24 (20 to 28)
Hyper- TG
  No 385 94 (24.4) 1.77 (1.22 to 2.57) 2926 32 (26 to 39)
  Yes 350 54 (15.4) 0.002 1 2630 21 (15 to 27)
BMI (kg/m2)
  18–<25 33 19 (57.6) 0.000 1 251 76 (46 to 118)
  25–<30 309 74 (23.9) 0.23 (0.11 to 0.49) 2342 32 (25 to 40)
  ≥30 389 55 (14.1) 0.12 (0.06 to 0.26) 2934 19 (14 to 24)
Continued
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of MetS, even if more benefits are obtained at a higher 
level of attained activity.27–30 The population included 
in the  di@ bet. es study cohort at baseline was not very 
active, and the subgroup with lower activity was associ-
ated with an increase in the rate of some components 
of the MetS.17 Our study is only observational, based on 
the two national strategies3 4 and whose main recommen-
dation is to be moderately active, such as walking daily 
and climbing stairs, which has been associated with an 
improvement in insulin sensitivity.
Our study identifies the characteristics that the popu-
lation has at baseline with a greater probability of MetS 
regression. Those are being women, presenting fewer 
numbers of MetS criteria at baseline, higher educational 
level and young age, while the absence of hypertension, 
hypertriglyceridemia and overweight/obesity identifies 
the population that is most susceptible to population 
interventions and in whom MetS is more likely to regress.
An important finding of our study is that it is necessary 
to achieve a higher degree of adherence to Med Diet, 
estimated at 11 points, in the same way as to reduce the 
occurrence of MetS. In relation to physical activity, it is 
also necessary to reach a minimum level of ≥2000 MET- 
min/week of physical activity to observe a tendency to 
regression. This is in agreement with results obtained in 
other studies and are important treatment objectives in 
patients with MetS.31–34
Limitations
The participants in the  di@ bet. es study cohort were 
randomly selected from the population covered by 
National Health System, divided in five different basic 
healthcare units, which included 100 clusters (primary 
healthcare centers) throughout the national territory, 
and the interventions carried out in each center have not 
specifically been evaluated. However, the monitoring of 
this cohort represents in real time the modifications that 
have arisen with population strategies and the response 
of the public health system. Differences due to the area 
of origin of the surveyed subjects have been analyzed; 
the studied population is representative of the Spanish 
population, but it is not enough to achieve representa-
tiveness of each specific area, of the five in which Spain 
was divided. This means that the results by zones must be 
taken with caution. There could also be an underdiagnosis 
in the declared interpretation of the subjects in relation 
to the pharmacological treatment of some components 
of the MetS, and this cannot be ruled out. The assess-
ment of diet and physical activity has been carried out 
by the IPAQ and MEDAS questionnaires, which may 
have some difficulty in their application. However, they 
were obtained both at baseline and during follow- up 
by the same nurses trained to carry out the surveys, so 
data collection is subject to less variability. The response 
rate during follow- up can also affect our results, but it 
has been more than 78% of those eligible, an important 
rate in this type of study, although the influence of some 
confounding factors cannot be ruled out.
CONCLUSIONS
Our data show that despite the designed popula-
tion strategies, the rate of MetS occurrence in Spain 
exceeds that of regression, increasing the existence 
of MetS by 257 people each day. The high prevalence 
of MetS makes it mandatory to implement national 
policies for its prevention. Preventive strategies to 
reduce the occurrence of MetS should focus on the 
At risk (n)
Regression to no 
MetS (n) P value OR (95% CI) Person- year
Incidence per 1000 
person- years (95% CI)
IPAQ
  High 118 28 (23.7) 0.534 1 893 31 (21 to 45)
  Moderate 248 49 (19.8) 0.79 (0.47 to 1.34) 1887 26 (20 to 34)
  Low 368 70 (19.0) 0.76 (0.46 to 1.24) 2768 25 (20 to 32)
MET- min/week
  >2000 222 51 (23.0) 0.113 1.29 (0.88 to 1.89) 1680 30 (23 to 40)
  <2000 512 96 (18.8) 1 3868 24 (20 to 30)
MEDAS
  <9 235 59 (25.1) 0.015 1 1777 33 (25 to 43)
  ≥9 500 89 (17.8) 0.65 (0.45 to 0.94) 3779 24 (19 to 29)
  >11 20 5 (25) 0.376 1.33 (0.48 to 3.73) 149 34 (11 to 78)
  ≤11 715 143 (20) 1 5406 26 (22 to 31)
Family history of T2DM
  No 302 64 (21.2) 0.251 1 2303 28 (21 to 36)
  Yes 408 77 (18.9) 0.87 (0.60 to 1.25) 3061 25 (20 to 31)
Data are n (%).
BMI, body mass index; HDL- chol, high- density lipoprotein cholesterol; IPAQ, International Physical Activity Questionnaire; MEDAS, MedDiet adherence screener; 
MET, metabolic equivalent of task; MetS, metabolic syndrome; T2DM, type 2 diabetes mellitus; TG, triglyceride.
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population older than 45 years and with one or two 
components of MetS, especially in overweight/obese 
people and those with central body fat distribution. 
The strategies to achieve a MetS regression are more 
likely to be successful in the population that has 
fewer MetS components, and in particular those who 
do not have hypertension, hypertriglyceridemia or 
a normal weight with peripheral fat distribution. It 
is necessary to achieve a greater adherence to Med 
Diet (>11 points) and at least 2000 MET- min/week 
of physical activity to observe a trend to the MetS 
regression, while >500 MET- min/week of physical 
activity may be sufficient to observe a reduction on 
its occurrence. These data must be considered by the 
public health system in Spain and may be of interest 
to apply them in other countries. It will also be useful 
for comparing data obtained from patients with other 
chronic diseases and across countries. Researcher 
should further investigate how the lifestyle can be 
optimized for health promotion and prevention of 
cardiometabolic conditions like MetS.
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